Lv41
470 积分 2023-08-09 加入
Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases
2天前
已完结
Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease
3天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial
4天前
已关闭
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial
4天前
已完结
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
5天前
已完结
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
5天前
已完结
Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer
5天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
5天前
已完结
An abnormal elevation of serum CA72-4 rather than other tumor markers can be caused by use of colchicine
15天前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
17天前
已完结
皖公网安备34019202002308
